Atantares, a Beijing, China-based developer of develop molecular chips, closed a Pre-A and Pre-A+ financing all around RMB100m.
The Pre-A round was led by Asia Green Fund, followed by Fosun Health Capital and existing investors Frees Fund, Qiming Venture Partners, Next Capital, and NeuX Capital. Pre-A+ was exclusively invested by Alibaba Health.
The company intends to use the funds for R&D of products, service operation, and capacity expansion.
Founded in 2021, Atantares aims to develop molecular chips by using integrated circuits or other semiconductor technologies to drive the semiconductor of biotechnology. The first application of the company is high-throughput DNA synthesis, aiming at reducing the cost of DNA synthesis through the gene synthesis technology of CMOS chips.
Nowadays the first generation of short-chain CMOS chips independently developed by Atantares has been taped out. In addition, the company has also strategically laid out the enzymatic biological method. These two methods are complementary paths for DNA synthesis. At present, the company is developing new controllable strategies to improve enzyme efficiency and automatic methods to adapt to enzymatic synthesis.
FinSMEs
02/08/2023